Oxygen deprivation, even for several minutes, can result in cell damage, organ dysfunction and, if prolonged, death.  Hemoglobin, the native protein responsible for transporting oxygen, is normally contained within circulating red blood cells (RBC). An RBC transfusion is the standard therapy for anemia resulting from blood loss or other disorders. Sources of RBCs for transfusions include stored supplies of donated blood (allogeneic blood) or of the recipient’s own pre-donated blood.

Unfortunately, there are frequently shortages of blood due to its limited shelf life and complications from blood typing such that blood is not available.1, 2 Shortages can become severe during crisis and, in some cases, blood is not an option.3 Many patients refuse blood transfusions on religious grounds,4 are alloimmunized, or simply prefer to avoid allogeneic blood transfusions, and as the population ages, the need for blood-intensive surgical procedures will increase sharply.

As such, an oxygen carrying solution might be needed when blood is either not available or not an option.



A hemoglobin carrying oxygen (HBOC) solution can act as an oxygen bridge during acute anemia as a support to when the patient can begin making his own RBCs or to when suitable blood becomes available. These products encompass the management of patients in many situations, whether from blood-loss,  ischemic conditions or other situations of oxygen deficiency.

They might provide benefit both in early or in late intervention, both systemically when there has been major blood loss or locally when blood flow is lost to a specific area. These  products do not treat or cure a disease state, but  support the basic metabolic function that is essential to sustain life.  Our drugs support the metabolism by providing an oxygen bridge treatment that allows the body to produce new RBCs or fight disease, whatever the case may be.  





1 Pitocco C, Sexton TR. Alleviating blood shortages in a resource-constrained environment. Transfusion. 2005 Jul;45(7):1118-26.

2 Thomas MJ. The management of overseas emergencies. Travel Med Infect Dis. 2007. Mar;5(2):1136.Epub 2006 Jun 19.

3 Luban NL. Transfusion safety: Where are we today? Ann N Y Acad Sci. 2005;1054:325-41. Review.

4 2006 Report of Jehovah’s Witnesses Worldwide. Jehovah’sWitnesOfficial Website.  Availableat:

http://www.watchtower.org/e/statistics/worldwide_report.htm  (Accessed 26 June 2007).


HbO2 Therapeutics LLC -  All Rights Reserved